Nkarta, Inc.
NKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 74.2% and free cash flow fell 29.2%, each against the same quarter a year earlier.
Follow NKTX
Nkarta, Inc. (NKTX) Altman Z-score
Nkarta, Inc.'s Altman Z-score for fiscal 2019 cannot be worked out: no share price in the week to the fiscal year end.
Altman Z-score, annual
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|
How fiscal 2019’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.61 | — | 0.73 | |
| Retained earnings / total assets | (0.55) | — | −0.77 | |
| EBIT / total assets | (0.46) | — | −1.52 | |
| Market value of equity / total liabilities | — | — | n/a | — |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | n/a — no share price in the week to the fiscal year end | — | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −1.29 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ALXO ALX Oncology Holdings Inc. compare | 154× |
| TARA Protara Therapeutics, Inc. compare | 7.3× |
| MOLN Molecular Partners AG Sponsored ADR compare | 2.7× |
| KRRO Korro Bio, Inc. compare | −6.7× |
| CUE Cue Biopharma, Inc. compare | −11.9× |
| NKTX Nkarta, Inc. | — |
| AVXL Anavex Life Sciences Corp. compare | — |
| TLSA Tiziana Life Sciences Ltd compare | — |
| ANTX AN2 Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets